Robotic Bronchoscopy for Peripheral Pulmonary Lesions
- Conditions
- Lung; Node
- Interventions
- Device: Robotic assisted bronchoscopy
- Registration Number
- NCT03727425
- Lead Sponsor
- Auris Health, Inc.
- Brief Summary
In this study, the feasibility of performing robotic navigation of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions will be evaluated.
- Detailed Description
Successful biopsy of peripheral pulmonary lesions remains a challenge due to a number of factors, one of which may be the ability to gain access to peripheral lesions due to the size and maneuverability of conventional bronchoscopes. In this study, the investigators will evaluate the feasibility of a new technique using a robotic endoscope with the Monarch navigational platform to both access and biopsy peripheral pulmonary lesions. The Monarch platform is a "robotic" assisted or electromechanical, software driven endoscopy system designed to be used by qualified physicians to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
- Capable and willing to give informed consent
- Acceptable candidate for an elective, non-emergent bronchoscopic procedure
- Solid peripheral lung lesions suspected of malignancy, between 1-5cm in size identified on thin slice CT scan within 14 days of the intended bronchoscopy procedure
- Lack bleeding disorders
- Medical contraindication to bronchoscopy
- Patients with a subsolid nodule and/or ground-glass opacity lesions on pre-procedure chest CT
- Patients with endobronchial involvement seen on chest CT
- Lack fitness to undergo flexible bronchoscopy as determined by the bronchoscopist prior to procedure
- Participation in any other investigational clinical trial (device or medication) 30 days before and throughout the duration of the study
- Uncontrolled or irreversible coagulopathy
- Female subjects who are pregnant or nursing or those of child-bearing potential refusing a pregnancy test
- Have significant mediastinal lymphadenopathy on chest CT scan and/or PET CT abnormalities suggestive of advanced stage lung cancer with mediastinal lymph node involvement
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Robotic assisted bronchoscopy Robotic assisted bronchoscopy Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
- Primary Outcome Measures
Name Time Method Successful Navigation to Targeted Peripheral Pulmonary Lesions During the procedure, approximately 1 hour Successful navigation is confirmed using radial probe endobronchial ultrasound (R-EBUS). the R-EBUS will be inserted into the working channel of the endoscope and advanced beyond the tip of the inner scope as the inner scope is advanced into the lung periphery towards the targeted lesion. As the endoscope is guided towards the targeted lesion, R-EBUS will confirm successful lesion localization prior to biopsies being performed.
Number of Participants With Device or Procedure Related Adverse Events 24-84 hours post-procedure Computed as the number of patients with device or procedure related adverse events divided by number of patients who underwent the robotic bronchoscopy procedure.
- Secondary Outcome Measures
Name Time Method Incidence of Complications Unrelated to Device 24-84 hours post-procedure Computed as the number of patients with events unrelated to device or procedure divided by number of patients who underwent the robotic bronchoscopy procedure.
Time to R-EBUS Confirmation (Lesion Localization) During the procedure, approximately 1 hour Defined by the time the robotic bronchoscope is inserted into the oropharynx until the localization of the targeted lesion is confirmed by REBUS.
Total Procedure Time During the procedure Defined by the time the robotic bronchoscope is inserted into the oropharynx until the time a biopsy tool is removed.
Diagnostic Yield Data was collected (as part of standard of care) through 1-year for calculation of diagnostic yield. Determined from the results of the bronchoscopy.
Trial Locations
- Locations (5)
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Innova Fairfax Hospital
🇺🇸Falls Church, Virginia, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States